Latanoprost TOA Ophthalmic Solution 0.005% w/v

Latanoprost TOA Ophthalmic Solution 0.005% w/v Special Precautions



Nitto Medic


Full Prescribing Info
Special Precautions
Careful Administration: (This product should be administered with special caution in the following patients.)
Aphakic patients, pseudophakic patients with a torn posterior lens capsule. (Macular edema, including cystoid macular edema and the decreased visual acuity associated with macular edema, have been reported.)
There is no experience in patients with severe or brittle asthma. Such patients should therefore be treated with caution until there is sufficient experience.
Patients with intraocular inflammation (iritis/uveitis).
Important Precautions: When this product is administered, the iris pigmentation may occur (due to increased melanin content). Before using this product, patients who receive treatment should be well informed of the possibility of the iris pigmentation and the change in iris color. It is reported that pigmentation is expected to increase gradually and stops after discontinuation of treatment. However, the resultant pigmentation is likely to be permanent.
In addition, iris color change due to the iris pigmentation may occur. In particular, the treatment of one eye may cause iris color difference between the right and left eyes.
This product should be administered with special caution in the patients with angle-closure glaucoma due to an insufficient clinical experience.
Benzalkonium chloride has been reported to cause eye irritation, dry eyes and may affect the corneal surface. Latanoprost "TOA" Ophthalmic Solution 0.005% should be used with caution in dry eye patients and in patients where the cornea may be compromised. In addition, monitoring is required with prolonged use in such patients.
Effects on ability to drive and use machines: Since blurred vision may temporarily occur after administration of the product, patients should be advised to refrain from operating machinery or driving a car until the symptoms recover.
Use in Children: The safety of this product in pediatric patients has not been established. (No clinical data are available for premature infants, newborns, and infants. Very limited clinical data are available for children.)
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in